Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Varespladib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A known ✓ | P14555 | 19/20 | 1.00 |
| ▸ | PLA2G1B | P04054 | 7/20 | 1.00 |
| ▸ | PLA2G10 | O15496 | 6/20 | 1.00 |
| ▸ | PLA2G2E | Q9NZK7 | 6/20 | 1.00 |
| ▸ | PLA2G5 | P39877 | 5/20 | 1.00 |
| ▸ | PLA2G2F | Q9BZM2 | 4/20 | 1.00 |
| ▸ | PLA2G2D | Q9UNK4 | 4/20 | 1.00 |
| ▸ | PLA2G6 | O60733 | 1/20 | 1.00 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 1.00 |
| ▸ | PLA2G12B | Q9BX93 | 1/20 | 1.00 |
| ▸ | PLA2G12A | Q9BZM1 | 1/20 | 1.00 |
| ▸ | PLA2G3 | Q9NZ20 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Varespladib SCHEMBL26726 | 1.00 | PLA2G2A (1.00) | PLA2G2APLA2G1BPLA2G10PLA2G2EPLA2G5 | |
| SCHEMBL7682372 | 0.93 | PLA2G2A (0.87) | PLA2G2APLA2G1BPLA2G10PLA2G2EPLA2G5 | |
| SCHEMBL818585 | 0.92 | PLA2G2A (1.00) | PLA2G2APLA2G1BPLA2G10PLA2G2EPLA2G5 | |
| SCHEMBL5150404 | 0.92 | PLA2G2A (0.84) | PLA2G2APLA2G1BPLA2G10PLA2G2EPLA2G5 | |
| Varespladib SCHEMBL1232548 | 0.91 | PLA2G2A (0.83) | PLA2G2APLA2G1BPLA2G10PLA2G2EPLA2G5 | |
| Varespladib SCHEMBL29430154 | 0.91 | PLA2G2A (0.83) | PLA2G2APLA2G1BPLA2G10PLA2G2EPLA2G5 | |
| Varespladib Methyl SCHEMBL29378302 | 0.91 | PLA2G2A (0.83) | PLA2G2APLA2G1BPLA2G10PLA2G2EPLA2G5 | |
| Varespladib Methyl SCHEMBL25678 | 0.91 | PLA2G2A (0.83) | PLA2G2APLA2G1BPLA2G10PLA2G2EPLA2G5 | |
| SCHEMBL6812616 | 0.90 | PLA2G2A (0.82) | PLA2G2APLA2G1BPLA2G10PLA2G2EPLA2G5 | |
| SCHEMBL5710700 | 0.90 | PLA2G2A (0.82) | PLA2G2APLA2G1BPLA2G10PLA2G2EPLA2G5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 196 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12564575-B2 | Early management, mitigation and prevention of sepsis and sepsis-like syndromes, including neo-natal ARDS due to infection, injury or iatrogenesis | OPHIREX, INC (US) | 2026-03-03 | — | — | US | claimed |
| WO-2025217379-A1 | DRUG TREATMENT FOR MACULAR DEGENERATION | UNIVERSITY OF ROCHESTER (US) | 2025-10-16 | — | — | WO | claimed |
| US-12383531-B2 | PLA2 inhibitors for treatment of pathological conditions caused by hymenoptera envenomation, such as hemolysis, cerebral edema, and acute kidney injury | OPHIREX, INC. (US) | 2025-08-12 | — | — | US | claimed |
| US-12285408-B2 | Methods and compositions for the treatment of snake bite | LIVERPOOL SCHOOL OF TROPICAL MEDICINE (GB) | 2025-04-29 | — | — | US | claimed |
| US-20250120950-A1 | USE OF SPLA2 INHIBITORS TO TREAT HYMENOPTERA ENVENOMATION, HEMOLYSIS, AND KIDNEY DISEASE, AND TO PROTECT BLOOD FROM OSMOTIC FRAGILITY | OPHIREX, INC. (US) | 2025-04-17 | — | — | US | claimed |
| US-20250120949-A1 | USE OF SPLA2 INHIBITORS TO TREAT ENVENOMATION BY SNAKES AND WASPS | OPHIREX, INC. (US) | 2025-04-17 | — | — | US | claimed |
| US-12274691-B2 | Envenomation therapies and related pharmaceutical compositions, systems and kits | OPHIREX, INC (US) | 2025-04-15 | — | — | US | claimed |
| US-20240382452-A1 | COMPOSITIONS AND DOSAGE FORMS FOR TOPICAL AND TRANSDERMAL DELIVERY OF ACTIVES AND METHODS OF USE | OPHIREX INC (US) | 2024-11-21 | — | — | US | claimed |
| US-20240294618-A1 | ANTI-VENOM ANTIBODIES AND USES THEREOF | CENTIVAX, INC. | 2024-09-05 | — | — | US | claimed |
| US-20240189317-A1 | ANTIVIRAL COMPOSITIONS AND METHODS | ACADIA WOODS PARTNERS, LLC | 2024-06-13 | — | — | US | claimed |
| CN-115803023-A | Method of treating patients infected with coronavirus with nerzetinib | 施万生物制药研发IP有限责任公司 | 2023-03-14 | — | — | CN | claimed |
| US-20230054792-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF SNAKE BITE | LIVERPOOL SCHOOL OF TROPICAL MEDICINE (GB) | 2023-02-23 | — | — | US | claimed |
| US-20220370411-A1 | EARLY MANAGEMENT, MITIGATION and PREVENTION OF SEPSIS and SEPSIS-LIKE SYNDROMES, INCLUDING NEO-NATAL ARDS DUE TO INFECTION, INJURY or IATROGENESIS | OPHIREX INC (US) | 2022-11-24 | — | — | US | claimed |
| CN-115379836-A | Early management and prevention of sepsis and sepsis-like syndrome | 奥菲瑞克斯公司 | 2022-11-22 | — | — | CN | claimed |
| US-20220331291-A1 | EARLY MANAGEMENT, MITIGATION and PREVENTION OF SEPSIS and SEPSIS-LIKE SYNDROMES, INCLUDING NEO-NATAL ARDS DUE TO INFECTION, INJURY or IATROGENESIS | OPHIREX INC (US) | 2022-10-20 | — | — | US | claimed |
| WO-2022217116-A1 | ANTI-VENOM ANTIBODIES AND USES THEREOF | CENTIVAX, INC. (US) | 2022-10-13 | — | — | WO | claimed |
| WO-2022197667-A1 | ANTIVIRAL COMPOSITIONS AND METHODS | YOUNG PETER R (US) | 2022-09-22 | — | — | WO | claimed |
| EP-4045026-A1 | EARLY MANAGEMENT AND PREVENTION OF SEPSIS AND SEPSIS-LIKE SYNDROMES | Ophirex, Inc. (US) | 2022-08-24 | — | — | EP | claimed |
| WO-2022031931-A2 | COMPOSITIONS FOR ALTERING A MICROGLIAL CELL, AND METHODS OF USE THEREFORE | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2022-02-10 | — | — | WO | claimed |
| WO-2022029334-A1 | COMBINATION THERAPIES FOR TREATING CORONAVIRUS INFECTION | GBIOTECH S.À.R.L. (CH) | 2022-02-10 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12274691-B2 | Envenomation therapies and related pharmaceutical compositions, systems and kits | PLA2R1, PLA2G12A, ACHE | PLA2G2A 11/4885PLA2G1B 13/4885PLA2G10 10/4885 |
| US-20240189317-A1 | ANTIVIRAL COMPOSITIONS AND METHODS | PIKFYVE, APAF1, API5 | PLA2G2A 2331/4885PLA2G1B 1568/4885PLA2G10 853/4885 |
| US-12383531-B2 | PLA2 inhibitors for treatment of pathological conditions caused by hymenoptera envenomation, such as hemolysis, cerebral edema, and acute kidney injury | PLA2G4A, PLA2G12A, PLA2G6 | PLA2G2A 4/4885PLA2G1B 6/4885PLA2G10 11/4885 |
| US-20250120950-A1 | USE OF SPLA2 INHIBITORS TO TREAT HYMENOPTERA ENVENOMATION, HEMOLYSIS, AND KIDNEY DISEASE, AND TO PROTECT BLOOD FROM OSMOTIC FRAGILITY | PLA2G12A, PLA2G2D, PLA2G2E | PLA2G2A 4/4885PLA2G1B 5/4885PLA2G10 10/4885 |
| US-12564575-B2 | Early management, mitigation and prevention of sepsis and sepsis-like syndromes, including neo-natal ARDS due to infection, injury or iatrogenesis | PLA2G12A, PLA2G3, PLA2G1B | PLA2G2A 19/4885PLA2G1B 3/4885PLA2G10 9/4885 |
| US-20220331291-A1 | EARLY MANAGEMENT, MITIGATION and PREVENTION OF SEPSIS and SEPSIS-LIKE SYNDROMES, INCLUDING NEO-NATAL ARDS DUE TO INFECTION, INJURY or IATROGENESIS | PLA2G12A, PLA2G3, PLA2G1B | PLA2G2A 19/4885PLA2G1B 3/4885PLA2G10 8/4885 |
| US-20250120949-A1 | USE OF SPLA2 INHIBITORS TO TREAT ENVENOMATION BY SNAKES AND WASPS | PLA2G12A, PLA2G2D, PLAAT2 | PLA2G2A 12/4885PLA2G1B 11/4885PLA2G10 18/4885 |
| US-20220370411-A1 | EARLY MANAGEMENT, MITIGATION and PREVENTION OF SEPSIS and SEPSIS-LIKE SYNDROMES, INCLUDING NEO-NATAL ARDS DUE TO INFECTION, INJURY or IATROGENESIS | PLA2G12A, PLA2G3, PLA2G1B | PLA2G2A 14/4885PLA2G1B 3/4885PLA2G10 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.